- Home
- RNGT vs BNTC Comparison
RNGT vs BNTC Comparison
Compare RNGT & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RNGT | BNTC |
|---|---|---|
| Founded | 2025 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 316.7M | 313.9M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RNGT | BNTC |
|---|---|---|
| Price | $10.20 | $9.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.33 |
| AVG Volume (30 Days) | 88.9K | ★ 190.1K |
| Earning Date | 01-01-0001 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.67 |
| EPS | ★ 0.00 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $101,900.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.90 | $8.52 |
| 52 Week High | $10.20 | $16.76 |
Technical Indicators
Market Signals| Indicator | RNGT | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 64.69 | 33.96 |
| Support Level | $9.95 | $8.89 |
| Resistance Level | N/A | $13.49 |
| Average True Range (ATR) | 0.00 | 0.76 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 100.00 | 20.00 |
Price Performance
Historical ComparisonAbout RNGT Range Capital Acquisition Corp II Class A Ordinary Shares
Range Capital Acquisition Corp II is a blank check company.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.